Atypical hemolytic uremic syndrome (aHUS) is a complement-mediated disorder, characterized by microangiopathic hemolysis, thrombocytopenia, and renal failure. It should be distinguished from typical diarrhea-associated hemolytic uremic syndrome, which is most commonly due to Shiga toxin--producing *Escherichia coli.* The incidence of aHUS is estimated at 0.23 per year per million people,^[@R1]^ but varies by population.^[@R2]--[@R6]^ Approximately 10--20% of aHUS diagnoses occur in the setting of pregnancy,^[@R7]--[@R9]^ where it has been termed *pregnancy-associated atypical hemolytic uremic syndrome*. Pregnancy is a complement amplifying condition,^[@R10]^ and maternal exposure to semi-allogenic fetoplacental material increases over gestation, with peak exposure at delivery.^[@R11]--[@R13]^ Excess complement activation is usually mitigated by soluble and membrane-bound regulators of the alternative complement pathway.^[@R14]--[@R16]^ However, inherited mutations in complement regulators predisposed to increased complement activation, and such mutations are common in pregnancy-associated aHUS.^[@R8],[@R9]^

In pregnancy and the postpartum period, recognition of pregnancy-associated aHUS is often delayed owing to misdiagnosis of similar thrombotic microangiopathy disorders, such as hemolysis, elevated liver enzymes, and low platelet count syndrome or thrombotic thrombocytopenic purpura (TTP).^[@R17]^ Delayed diagnosis results in delayed treatment, which can be life-threatening. Corticosteroids and plasma exchange are sometimes effective, but pregnancy-associated aHUS often progresses to end-stage renal disease, dialysis, or kidney transplant.^[@R9]^ Eculizumab, a monoclonal antibody against complement protein C5, is effective for treatment of aHUS^[@R18],[@R19]^ and received U.S. Food and Drug Administration (FDA) approval for this indication in 2011. However, pregnant women were excluded from clinical trials.^[@R20]^ Thus, data on pregnancy-associated aHUS treated with eculizumab are limited, with only four cases reported from an international registry.^[@R9]^ Therefore, we sought to perform a systematic review of pregnancy-associated aHUS case reports, to better characterize disease presentation, diagnosis, treatment, and clinical outcomes, before and after FDA approval of eculizumab for treatment of aHUS in 2011.

SOURCES {#s1}
=======

A systematic review of the literature was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and was registered with PROSPERO (registration number CRD42019129266). The primary objective of the search strategy was to identify cases of pregnancy-associated aHUS. English-language articles published until March 2018 were searched in the following databases: PubMed, MEDLINE, Cochrane Library, [ClinicalTrials.gov](http://ClinicalTrials.gov), Web of Science, EMBASE and Google Scholar. The search criteria used the following MeSH terms: "thrombotic microangiopathy," "TMA," "hemolytic uremic syndrome," "HUS," "atypical hemolytic uremic syndrome," "aHUS," "pregnancy," "postpartum," and "peripartum." We did not exclude studies based on study design, location, or any other criteria. In addition, we reviewed reference lists of relevant articles to identify additional case studies.

STUDY SELECTION {#s2}
===============

All titles and abstracts of search results were independently screened and assessed for inclusion into the systematic review by two study authors (M.G. and S.G.). Cases of disagreement were reviewed and adjudicated by a third author (R.M.B.) to reach consensus. Articles were eligible for inclusion if full texts were available either through public or institutional access, or on request from the corresponding author. Articles were excluded for the following reasons: 1) not relevant to the study question or review article without original case data; 2) cases of thrombotic thrombocytopenic purpura--hemolytic uremic syndrome (TTP-HUS) and article failed to clarify a final diagnosis of either TTP or aHUS; 3) alternative etiology for HUS, such as Shiga toxin-producing *E coli* or scleroderma renal crisis; 4) case series or cohort studies without description of individual cases. For reports describing outcomes of subsequent pregnancies, the index pregnancy was evaluated as primary, first-episode pregnancy-associated aHUS and subsequent pregnancies were evaluated as known aHUS before conception.

Data abstracted from case reports included corresponding author information, journal reference, year of publication, patient characteristics (age, parity, pertinent family or medical histories), pregnancy and delivery characteristics (timing and mode of delivery and pregnancy or delivery complications), timing of disease presentation, diagnostic evaluation (laboratory testing, renal biopsy, and complement genetic testing), therapeutic approach (blood product transfusions, corticosteroids, dialysis, plasma exchange, and eculizumab), and maternal and neonatal outcomes. For patients treated with eculizumab, data were collected on dosing regimen and duration of treatment. Laboratory measures were abstracted as nadir values for hemoglobin, platelet count, or peak values for lactate dehydrogenase, alanine transaminase (ALT), aspartate transaminase (AST), and creatinine. We also abstracted data for ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is used to diagnose TTP (activity level below 10%). Neonatal outcomes were reported as liveborn or stillborn, or in early pregnancy cases whether pregnancy-associated aHUS followed abortion (spontaneous or therapeutic) or ectopic pregnancy. For maternal outcomes, remission was determined by the final condition reported by the authors. Case studies were included if there were enough data to confirm the diagnosis of pregnancy-associated aHUS and treatment approach. Data on all variables were not required for inclusion, and unavailable data were listed as not available.

Data were described using means with SD, medians with interquartile range, and percentages, as was appropriate to the data characteristics (dichotomous or continuous) or distribution (normal or nonnormal). Statistical testing was performed using χ^2^ or Fisher exact test, *t*-test, or Wilcoxon rank-sum test, with significance at *P*\<.05. Data were analyzed with Stata 15.0.

RESULTS {#s3}
=======

Our initial search yielded 796 unique citations. After exclusions, 48 articles were included, with 60 unique cases of pregnancy-associated aHUS (Fig. [1](#F1){ref-type="fig"}) (Zschiedrich S, Prager EP, Kuehn EW. Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab \[letter\]. Ann Intern Med 2013;159:76.).^[@R21]--[@R40],[@R41]--[@R67]^ In four cases, outcomes of subsequent pregnancies were reported,^[@R41],[@R55],[@R60]^ for a total of 66 pregnancies. Fifty-four cases described first-episode (new diagnosis) aHUS in pregnancy (n=3) or postpartum (n=51) (Table [1](#T1){ref-type="table"}). Twelve cases described pregnancy in women with a known diagnosis of aHUS (Table [2](#T2){ref-type="table"}).

![Flow diagram of case report selection. TTP-HUS, thrombotic thrombocytopenic purpura--hemolytic uremic syndrome; HUS, hemolytic uremic syndrome; aHUS, atypical hemolytic uremic syndrome.\
Gupta. Pregnancy-Associated Hemolytic Uremic Syndrome. Obstet Gynecol 2019.](ong-135-46-g001){#F1}

###### 

Data for Patients With First-Episode Pregnancy-Associated Atypical Hemolytic Uremic Syndrome
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###### 

Data for Patients With a Known Diagnosis of Atypical Hemolytic Uremic Syndrome Before Pregnancy
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For our initial assessment, we evaluated women with first-episode pregnancy-associated aHUS. In four cases, the timing of diagnosis was not specified. Diagnosis was predominantly in the postpartum period (47/50, 94%), at median (interquartile range) postpartum day 2 (1--4). When stated, first-episode pregnancy-associated aHUS occurred more often after cesarean delivery (33/47, 70%), in nulliparous women (22/38, 58%), with mean (SD) maternal age 29.0 (6.2) years and delivery gestational age 36.4 (2.7) weeks. Four cases occurred after an early pregnancy loss or termination. Of these, two occurred after uncomplicated dilation and curettage,^[@R63]^ one after a complicated dilation and curettage procedure necessitating exploratory laparotomy and hysterectomy,^[@R65]^ and one after a ruptured tubal ectopic pregnancy necessitating exploratory laparotomy and massive transfusion.^[@R31]^

The diagnosis of pregnancy-associated aHUS was usually suspected based on markedly abnormal laboratory findings, including: median (interquartile range) concentration of serum lactate dehydrogenase 2,438 (1,235--3,885) units/L; hemoglobin 6.8 (6.1--7.8) g/dL; platelet count 43 (30--61) k/microliter; and creatinine 5.4 (4.1--7.6) mg/dL. Laboratory testing was often triggered by symptoms such as nausea, vomiting, abdominal pain, headache, shortness of breath, or elevated blood pressure. Liver enzymes (ALT, AST) were reported in 17 cases, and levels were more than twice the upper limit of normal in 52% (9/17) of cases, with median (interquartile range): ALT 47 (28--333) units/L; AST 114 (20--373) units/L. In 19 cases, haptoglobin was assessed to confirm red cell hemolysis and levels were low or undetectable in all instances (19/19, 100%). Microangiopathic hemolysis was confirmed by detection of schistocytes on peripheral smear (46/47, 98%).

For our initial analysis of first-episode pregnancy-associated aHUS, we stratified cases into two groups: group 1 (n=37), in which eculizumab was not used for treatment, and group 2 (n=17), in which eculizumab was used for treatment. Before and after introduction of eculizumab in 2011, maternal age, parity, gestational age at delivery, and timing of diagnosis were similar (Table [3](#T3){ref-type="table"}). The median (interquartile range) postpartum day of diagnosis was 2.0 (0--8.0) before eculizumab and 1.0 (1.0--3.5) after eculizumab, and this difference was not significant. Among reports in which pregnancy outcomes were reported and the pregnancy was carried beyond 24 weeks of gestation, the diagnosis of pregnancy-associated aHUS was often preceded by a pregnancy complication: hypertension or preeclampsia (21/37, 57%); obstetric hemorrhage (8/37, 22%); or intrauterine fetal death (7/25, 28%). Obstetric complications were not significantly different in pregnancy-associated aHUS cases reported before or after introduction of eculizumab.

###### 

Characteristics and Pregnancy Complications in First-Episode Pregnancy-Associated Atypical Hemolytic Uremic Syndrome
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Although the diagnosis of pregnancy-associated aHUS was suspected based on clinical symptoms and laboratory findings, other studies were often used to confirm the diagnosis or rule out other etiologies, including renal biopsy, ADAMTS13 activity level, and complement genetic testing. Before introduction of eculizumab in 2011, 49% of pregnancy-associated aHUS diagnoses were made by clinical criteria alone and 44% incorporated renal biopsy findings, but these numbers have dipped since 2011, to 35% and 24%, respectively (Table [4](#T4){ref-type="table"}). Renal biopsy was often used to confirm a diagnosis of thrombotic microangiopathy, and findings included fibrin thrombi within glomeruli, luminal stenosis in arterioles, subendothelial swelling, mesangiolysis, and fragmented erythrocytes. The decline in use of renal biopsy was countered by a marked increase in both ADAMTS13 activity testing and complement genetic testing after eculizumab was introduced into practice (19% vs 82%, *P*\<.001). ADAMTS13 activity level was above 10% in all 21 cases of pregnancy-associated aHUS in which it was tested, ruling out TTP. This emphasizes the value of ADAMTS13 testing to rule out TTP and to help expedite the diagnosis of aHUS.

###### 

Diagnosis, Treatment, and Long-Term Outcomes in First-Episode Pregnancy-Associated Atypical Hemolytic Uremic Syndrome

![](ong-135-46-g007)

Complement factor H risk variants were the most common genetic abnormality reported before introduction of eculizumab in 2011. Five of seven cases were reported by the same author, who also reported concomitant thrombomodulin risk variants in three cases.^[@R57]^ As complement genetic panels have expanded, case studies have described additional variants in pregnancy-associated aHUS. Some of these findings, summarized in Table [1](#T1){ref-type="table"}, include heterozygous complement factor I frameshift mutation (Zschiedrich S et al. Ann Intern Med 2013;159:76.), heterozygous CD46 variant,^[@R52]^ and homozygous deletion in complement factor H--related genes 1 and 3 (*CFHR1*-*CFHR3* deletion).^[@R30]^

Next, we sought to compare the treatment approach to pregnancy-associated aHUS before and after introduction of eculizumab in 2011 (Table [4](#T4){ref-type="table"}). Use of corticosteroids and dialysis were similar between the two groups, and there was a slight, but nonsignificant decrease in use of blood transfusion with eculizumab (68% vs 41%, *P*=.07). There has been an increase in the reported use of plasma exchange after introduction of eculizumab (60% vs 100%, *P*=.002). However, in all 17 cases in which eculizumab was used for treatment of pregnancy-associated aHUS, it was given after plasma exchange had failed. Moreover, eculizumab was usually a second- or third-line treatment after intravenous (IV) corticosteroids, plasma exchange, or hemodialysis.

In the majority (15/17, 88%) of cases of first-episode pregnancy-associated aHUS in which eculizumab was used, both diagnosis and treatment occurred in the postpartum period. Only two women were newly diagnosed with pregnancy-associated aHUS and treated with eculizumab in the antepartum period, at 10^[@R22]^ and 17 weeks of gestation.^[@R35]^ The eculizumab regimen was not stated for the latter, but Andries et al used the FDA-approved regimen for treatment of aHUS, which is eculizumab 900 mg IV weekly for 4 weeks (loading regimen), then 1,200 mg IV in week 5 followed by 1,200 mg IV every other week (maintenance regimen). Of the 15 women treated with eculizumab in the postpartum period, the standard loading regimen was used in 12 (80%) but was unspecified in three others. The standard maintenance regimen was used in 11 patients (73%); the maintenance regimen was unspecified in two patients, and was reported as 900 mg IV twice weekly in one^[@R33]^ and 1,200 mg IV monthly in another.^[@R62]^

Table [4](#T4){ref-type="table"} also describes long-term outcomes in women after first-episode pregnancy-associated aHUS. More women achieved disease remission when treated with eculizumab compared with those not treated with eculizumab (88% vs 57%, *P*=.02). In addition, among 17 cases of pregnancy-associated aHUS treated with eculizumab, there were no reports of persistent renal failure, dialysis, or death, compared with 24% (9/37) of such cases not treated with eculizumab (two maternal deaths, seven end-stage renal disease or dialysis). In eight cases, postpartum treatment with eculizumab was stopped at a median (range) of 7 (1--22) months; in four cases, treatment was ongoing at 7, 7, 20, and 22 months. In other cases, treatment duration was not specified.

We separately assessed characteristics and outcomes of women with known aHUS entering pregnancy (Table [2](#T2){ref-type="table"}). There were eight unique cases, with a total of 12 pregnancies. Seven cases, and 10 pregnancies, were in women with a known complement mutation or deficiency, most commonly complement factor H (n=4) or complement factor I (n=3). Nine women were treated with eculizumab during pregnancy. Mean (SD) age at pregnancy was 29.1 (4.4) years, with median (range) starting creatinine 1.9 (0.8--3.4) mg/dL. Only one case started pregnancy with a normal serum creatinine below 1.2 mg/dL,^[@R37]^ but baseline creatinine was not reported in five pregnancies. Recurrence of aHUS occurred in 67% (8/12) of pregnancies, leading to pregnancy termination in two instances^[@R55],[@R60]^ and preterm birth in three others.^[@R41],[@R55]^ In two pregnancies, recurrence occurred postpartum.^[@R34],[@R37]^ There was only one pregnancy (1/12, 8%) with aHUS that resulted in a healthy term delivery, without pregnancy complication or disease recurrence.^[@R41]^ However, in that case, the subsequent pregnancy was complicated by recurrent aHUS at 28 weeks of gestation and premature delivery at 30 weeks. As expected, in three women (six pregnancies) with chronic kidney disease entering pregnancy (all creatinine at or above 1.5 mg/dL), pregnancy outcomes were particularly poor, with deliveries at 12, 24, 29, 30, 30, and 34 weeks of gestation.^[@R55]^

DISCUSSION {#s4}
==========

We have summarized data for 54 unique cases of first-episode aHUS occurring in pregnant or postpartum women (pregnancy-associated aHUS), of whom 17 patients were treated with eculizumab. In addition, we assessed 12 pregnancies in women with known aHUS before conception, of whom nine were treated with eculizumab. We find that, despite similar clinical characteristics to women not treated with eculizumab, those treated with eculizumab for first-episode pregnancy-associated aHUS had higher rates of disease remission with no cases of persistent renal failure, dialysis, or maternal death. Moreover, successful treatment of first-episode pregnancy-associated aHUS with eculizumab usually occurred despite failure of other modalities such as plasma exchange, corticosteroids, and hemodialysis.

Clinical trials have shown that eculizumab effectively decreases complement-mediated hemolysis, thrombocytopenia, and kidney injury in nonpregnant adults with aHUS.^[@R20],[@R68]^ Thus, successful treatment of pregnancy-associated aHUS with eculizumab is in line with our understanding of the disease as a complement-mediated thrombotic microangiopathy disorder. International registry data have shown that pregnancy-associated aHUS is like adult aHUS in nearly all aspects and should be treated similarly.^[@R8],[@R9]^ Although a minority of pregnancy-associated aHUS cases occurred after an uncomplicated pregnancy, preceding obstetric complications were common and included preeclampsia, hemorrhage, and fetal death. Thus, a major limitation to expedited diagnosis and treatment of pregnancy-associated aHUS may be co-occurrence with other pregnancy complications. It is important to study these cases because preeclampsia and hemorrhage may trigger development of pregnancy-associated aHUS, particularly in those with complement gene mutations. However, pregnancy-associated aHUS is a clinical diagnosis based on the clinical phenotype, and genetic testing is not required. Although other etiologies should be evaluated and ruled out, we found a very characteristic pattern of laboratory values in first-episode pregnancy-associated aHUS, including microangiopathic hemolysis (elevated lactate dehydrogenase, low haptoglobin, schistocytes), thrombocytopenia, and severe renal failure. This triad should alert the health care provider to the diagnosis of pregnancy-associated aHUS, especially if laboratory parameters worsen, rather than improve, in the postpartum period. When obstetricians suspect pregnancy-associated aHUS, they should involve other health care providers with expertise in diagnosing and treating aHUS, and this may include maternal--fetal medicine, nephrology, hematology, or critical care physicians.

Atypical hemolytic uremic syndrome is a complement-mediated disorder that is best treated with complement blockade,^[@R68]^ yet we found that plasma exchange was often used as a first-line option for pregnancy-associated aHUS, even after FDA approval of eculizumab. Although the American Society for Apheresis states that the role of therapeutic plasma exchange in treatment of aHUS is not established,^[@R69]^ the decision to start plasma exchange may be driven by the desire to treat TTP presumptively until it can be ruled out. Like aHUS, TTP is a life-threatening thrombotic microangiopathy disorder, but unlike aHUS, TTP is best treated with plasma exchange because it is usually due to ADAMTS13 autoantibodies.^[@R70]--[@R73]^ Thrombotic thrombocytopenic purpura can be easily ruled out with an ADAMTS13 activity level greater than 10% and the absence of autoantibodies. Likewise, complement genetic testing may be performed to support a diagnosis of aHUS, particularly when a pathogenic mutation is discovered. However, ADAMTS13 and complement genetic testing are send-out labs in most institutions, limiting turnaround time. To expedite diagnosis and treatment of aHUS, and to help rule out TTP more quickly, it may be beneficial for clinicians to work with their laboratory medicine department and hospital leadership to review options for ADAMTS13 and complement genetic testing. Until a diagnosis of pregnancy-associated aHUS can be made with reasonable certainty, the initial treatment approach should be made on a case-by-case basis. Once the diagnosis of pregnancy-associated aHUS is made, eculizumab should be considered for on-label treatment as it appears to improve long-term remission of disease when compared with women with pregnancy-associated aHUS not treated with eculizumab.

Our data are limited by the nature of case reports, which are rich in detail but biased by a lack of control data. There may be a publication bias toward cases with a positive outcome or an unusual feature, such as a newly described genetic variant. Thus, these cases may not be a fully representative sample. Some reports in our analysis were also hindered by missing data (eg, parity, gestational age) or lack of long-term follow-up. However, our data set has many strengths. It is the largest compilation to-date of pregnancy-associated aHUS cases treated with eculizumab, and it is the largest study of first-episode pregnancy-associated aHUS cases that included all women regardless of obstetric history. Inclusion of women with obstetric complications such as preeclampsia, hemorrhage, and fetal death allowed us to demonstrate the variety of ways in which pregnancy-associated aHUS may present---an important aspect that has been missing from registry reports. Finally, it is important to note that eculizumab is a high-cost drug that may not be readily available at every institution and despite on-label use, insurance coverage may vary. Health care providers considering using eculizumab should work with the pharmacy department to discuss drug access, inpatient cost considerations, plan for outpatient infusions, and long-term follow-up.

In assessing our data, we wish to emphasize that, once someone is diagnosed with aHUS or pregnancy-associated aHUS, the prognosis for future pregnancies is guarded. Our data suggest that women with aHUS who develop chronic kidney disease, particularly with serum creatinine at or above 1.5 mg/dL, have particularly poor pregnancy outcomes and a high rate of recurrent disease. Although women with well-controlled aHUS may be able to achieve successful pregnancy outcomes in the era of eculizumab, such data are extremely limited. Pregnancy care, and decisions regarding future pregnancy, should be made in conjunction with obstetrician-gynecologists, maternal--fetal medicine specialists, hematologists, and nephrologists, among others. Both aHUS and pregnancy-associated aHUS are serious, life-threatening thrombotic microangiopathy disorders, and women stand to benefit greatly from care that is guided by an expert, multidisciplinary team.
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